Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial

Table 3 Secondary outcomes

Incidence measures	Maternal IPTp arm	Number of cases (incidence PPY)	IRR (95% CI)	p value
Complicated malaria	SP	44 (0.145)	0.54 (0.32–0.92)	0.02
	DP	24 (0.078)
All-cause hospitalisations	SP	19 (0.062)	0.39 (0.15–1.05)	0.06
	DP	8 (0.026)
Infant mortality	SP	9 (0.030)	0.45 (0.03–7.88)	0.59
	DP	7 (0.023)
Non-malarial febrile illnesses	SP	1022 (3.36)	1.01 (0.91–1.12)	0.87
	DP	1047 (3.39)
Prevalence measures^a	Maternal IPTp arm	Prevalence (%)	PR (95% CI)	p value
Parasitemia^b	SP	344/3879 (8.9%)	1.02 (0.83–1.27)	0.84
	DP	357/3933 (9.1%)
Anemia^c	SP	222/878 (25.3%)	0.96 (0.79–1.17)	0.70
	DP	216/892 (24.2%)

CI confidence interval, DP dihydroartemisinin-piperaquine, IPTp intermittent preventive treatment of malaria in pregnancy, IRR incidence rate ratio, PPY per person-year, PR prevalence ratio, SP sulfadoxine-pyrimethamine
^aPrevalence measures are period prevalence
^bProportion of blood smears with parasitemia measured routinely every 4 weeks starting at 4 weeks of age
^cDefined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age

ISSN: 1741-7015